We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biosearch Technologies Acquires European Companies VitraBio and DNA Technology

By LabMedica International staff writers
Posted on 26 Feb 2013
Biosearch Technologies, Inc. More...
(Novato, CA, USA), a leading supplier of customized oligonucleotides, specialty amidites, and CPGs (controlled-pore glass) to the research and diagnostics markets, has acquired the oligonucleotide manufacturing division of the company DNA Technology, A/S (Aarhus, Denmark) and CPG manufacturer VitraBio, GmbH (Steinach, Germany).

Biosearch, with the acquisition of DNA Technology, has added a highly accomplished production team with a quality system and an established European customer base concentrated in the Nordic countries. DNA Technology is focused on the production of modified oligos, and will take advantage of the full access to the range of specialty modifications generated by Biosearch. Furthermore, Biosearch will provide cutting edge manufacturing applications and access to its large intellectual property (IP) range, enabling DNA Technology to expand production capabilities and product range to better serve a growing customer base.

With the acquisition of German controlled-pore glass (CPG) manufacturer VitraBio in September 2011, Biosearch gains control over VitraBio’s sophisticated CPG manufacturing technology and innovative production facility, which expands its already extensive range of oligo synthesis tools and processes. Biosearch plans to bring chemical manufacturing capabilities to VitraBio’s Steinach facility to enhance existing US production of specialty amidites and modified CPGs, in addition to continuing production of DNA/RNA synthesis supports for the research and therapeutic oligo markets.

The acquisition of DNA Technology and VitraBio denotes Biosearch’s increasing focus on supporting European biotechnology and diagnostic markets. Furthermore, Biosearch has secured significant manufacturing redundancy for its North American operations as well as a strong base from which to expand sales, production, and regulated contract-manufacturing capabilities throughout Europe.

Established in 1992, DNA Technology is a provider of custom-made synthetic oligonucleotides in the Nordic countries. A key focus of the company is the production of highly modified synthetic DNA and RNA to serve life science research and healthcare markets. The company is currently ISO 9001:2008 certified, and first certified to the ISO 9002 standard in 1997. DNA Technology moved in 2007 to a newly renovated facility in Risskov, a suburban district of the city of Aarhus.

Founded in 2003, VitraBio is an ISO 9001:2008-certified company and it is one of the few who possess the expertise and IP range to manufacture highly specialized controlled-pore glass (CPG) typically utilized as a support in solid-phase oligonucleotide synthesis. The manufacturing plant is suited for large-scale manufacturing of CPGs and phosphoramidites and provides ample space for continued expansion of production activities.

Biosearch Technologies is an ISO 9001:2008-certified company founded in 1993, Biosearch is focused on the design, development, and manufacture of advanced oligonucleotide-based tools. Products include fluorophores (CAL Fluor, Quasar, and Pulsar dyes) and dark quenchers (Black Hole Quencher dyes) to be included in custom-synthesized probe formats for real-time, quantitative PCR, Stellaris RNA fluorescence in situ hybridization (FISH), and other genomic-based applications. Biosearch’s markets include pharmaceutical, in vitro diagnostic, biotechnology, ag/bio, environmental and food testing, public health, and biodefense sectors.

Related Links:

Biosearch Technologies
DNA Technology
VitraBio




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.